Tuuli Ranki

1.5k total citations
22 papers, 716 citations indexed

About

Tuuli Ranki is a scholar working on Genetics, Oncology and Molecular Biology. According to data from OpenAlex, Tuuli Ranki has authored 22 papers receiving a total of 716 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Genetics, 15 papers in Oncology and 13 papers in Molecular Biology. Recurrent topics in Tuuli Ranki's work include Virus-based gene therapy research (17 papers), CAR-T cell therapy research (13 papers) and Cancer Research and Treatments (10 papers). Tuuli Ranki is often cited by papers focused on Virus-based gene therapy research (17 papers), CAR-T cell therapy research (13 papers) and Cancer Research and Treatments (10 papers). Tuuli Ranki collaborates with scholars based in Finland, United States and Germany. Tuuli Ranki's co-authors include Akseli Hemminki, Anna Kanerva, Lotta Kangasniemi, Merja Särkioja, Sari Pesonen, Mari Raki, Tanja Hakkarainen, Ari Ristimäki, Vincenzo Cerullo and R A Desmond and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.

In The Last Decade

Tuuli Ranki

21 papers receiving 702 citations

Peers

Countries citing papers authored by Tuuli Ranki

Since Specialization

Citations

This map shows the geographic impact of Tuuli Ranki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tuuli Ranki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tuuli Ranki more than expected).

Fields of papers citing papers by Tuuli Ranki

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tuuli Ranki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tuuli Ranki. The network helps show where Tuuli Ranki may publish in the future.

Co-authorship network of co-authors of Tuuli Ranki

This figure shows the co-authorship network connecting the top 25 collaborators of Tuuli Ranki. A scholar is included among the top collaborators of Tuuli Ranki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tuuli Ranki. Tuuli Ranki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Real-world Evidence of Multiple Myeloma Treated from 2013 to 2019 in the Hospital District of Helsinki and Uusimaa, Finland 2023 ·Future Oncology ·(unknown), Kristiina Uusi-Rauva, Tuuli Ranki, Iiro Toppila, (unknown), (unknown), Lotta Vassilev, Kimmo Porkka, Raija Silvennoinen, Oscar Brück	2
2	Retrospective, Registry-based, Cohort Investigation of Clinical Outcomes in Patients with Cutaneous Squamous Cell Carcinoma and Basal Cell Carcinoma in Finland 2022 ·Acta Dermato Venereologica ·Samuli Tuominen, Liisa Ukkola‐Vuoti, Pilvi Riihilä, (unknown), Veli‐Matti Kähäri, Mariann I. Lassenius, Tuuli Ranki, (unknown), Lotta Vassilev, S. Vuoti, Kalle Mattila	1
3	Characterization of a novel OX40 ligand and CD40 ligand-expressing oncolytic adenovirus used in the PeptiCRAd cancer vaccine platform 2021 ·Molecular Therapy — Oncolytics ·Erkko Ylösmäki, (unknown), Manlio Fusciello, Beatriz Martins, (unknown), (unknown), (unknown), Sara Feola, Anna Kreutzman, Tuuli Ranki, Julia Karbach, Tapani Viitala, (unknown), Elke Jäger, Sari Pesonen, Vincenzo Cerullo	37
4	Exploiting Preexisting Immunity to Enhance Oncolytic Cancer Immunotherapy 2020 ·Cancer Research ·Siri Tähtinen, Sara Feola, Cristian Capasso, (unknown), Christianne Groeneveldt, Erkko Ylösmäki, (unknown), Beatriz Martins, Manlio Fusciello, Marta Medeot, Maria Tagliamonte, Jacopo Chiaro, Firas Hamdan, Karita Peltonen, Tuuli Ranki, Luigi Buonaguro, Vincenzo Cerullo	40
5	Toxicological and bio-distribution profile of a GM-CSF-expressing, double-targeted, chimeric oncolytic adenovirus ONCOS-102 – Support for clinical studies on advanced cancer treatment 2017 ·PLoS ONE ·Łukasz Kuryk, Lotta Vassilev, Tuuli Ranki, Akseli Hemminki, Aila Karioja‐Kallio, (unknown), (unknown), Vincenzo Cerullo, Sari Pesonen	32
6	Abstract A034: Boosting the efficacy of PD-L1 blockade with oncolytic vaccine for improved antitumor responses in melanoma 2016 ·Cancer Immunology Research ·Cristian Capasso, Siri Tähtinen, (unknown), Sara Carpi, Manlio Fusciello, (unknown), (unknown), Karita Peltonen, Beatriz Martins, (unknown), Sari Pesonen, Tuuli Ranki, Łukasz Kuryk, Erkko Ylösmäki, Vincenzo Cerullo	1
7	661. Synergistic Anti-Tumor Efficacy of Immunogenic Adenovirus ONCOS-102 and Standard of Care Chemotherapy in Preclinical Mesothelioma Model 2016 ·Molecular Therapy ·Łukasz Kuryk, Elina Haavisto, Mariangela Garofalo, Cristian Capasso, Mari Hirvinen, Sari Pesonen, Tuuli Ranki, Lotta Vassilev, Vincenzo Cerullo	3
8	Synergistic anti‐tumor efficacy of immunogenic adenovirus ONCOS‐102 (Ad5/3‐D24‐GM‐CSF) and standard of care chemotherapy in preclinical mesothelioma model 2016 ·International Journal of Cancer ·Łukasz Kuryk, Elina Haavisto, Mariangela Garofalo, Cristian Capasso, Mari Hirvinen, Sari Pesonen, Tuuli Ranki, Lotta Vassilev, Vincenzo Cerullo	45
9	Local immunotherapy with ONCOS-102 shapes harmful tumor associated CD68+ macrophages to become beneficial cells that correlate with increased overall survival 2015 ·Journal for ImmunoTherapy of Cancer ·Sari Pesonen, Johan Lundin, Nina Linder, Riku Turkki, Ari Ristimäki, Timo Joensuu, Kalevi Kairemo, Kaarina Partanen, Tuomo Alanko, Elke Jäger, Julia Karbach, Claudia Wahle, Akseli Hemminki, (unknown), Mikael von Euler, Tiina Hakonen, Tuuli Ranki, (unknown), Magnus Jäderberg, Dmitriy Zamarin	1
10	Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients 2012 ·Cancer Research ·Sari Pesonen, Iulia Diaconu, Lotta Kangasniemi, Tuuli Ranki, Anna Kanerva, Saila K. Pesonen, Ulrike Gerdemann, Ann M. Leen, Kalevi Kairemo, Minna Oksanen, Elina Haavisto, Liisa Holm, Aila Karioja‐Kallio, Satu Kauppinen, Kaarina Partanen, Leena Laasonen, (unknown), Tuomo Alanko, Vincenzo Cerullo, Akseli Hemminki	107
11	Serotype Chimeric Human Adenoviruses for Cancer GeneTherapy 2010 ·Viruses ·Tuuli Ranki, Akseli Hemminki	16
12	Tissue-Specific Promoters Active in CD44+CD24−/low Breast Cancer Cells 2008 ·Cancer Research ·Gerd Bauerschmitz, Tuuli Ranki, Lotta Kangasniemi, Camilla Ribacka, Minna Eriksson, (unknown), (unknown), Ari Ristimäki, Pekka Virkkunen, Maija Tarkkanen, Tanja Hakkarainen, Anna Kanerva, Daniel Rein, Sari Pesonen, Akseli Hemminki	83
13	Systemic efficacy of oncolytic adenoviruses in imagable orthotopic models of hormone refractory metastatic breast cancer 2007 ·International Journal of Cancer ·Tuuli Ranki, Merja Särkioja, Tanja Hakkarainen, Karl von Smitten, Anna Kanerva, Akseli Hemminki	36
14	Luciferase imaging for evaluation of oncolytic adenovirus replication in vivo 2007 ·Gene Therapy ·Kilian Guse, João D. Dias, Gerd Bauerschmitz, (unknown), Einari Aavik, Tuuli Ranki, (unknown), Merja Särkioja, R A Desmond, Anna Kanerva, Akseli Hemminki	27
15	Chlorpromazine and apigenin reduce adenovirus replication and decrease replication associated toxicity 2006 ·The Journal of Gene Medicine ·Anna Kanerva, Mari Raki, Tuuli Ranki, Merja Särkioja, (unknown), Renée A. Desmond, (unknown), Ulf‐Håkan Stenman, Helena Isoniemi, Krister Höckerstedt, Ari Ristimäki, Akseli Hemminki	23
16	Noninvasive imaging for evaluation of the systemic delivery of capsid‐modified adenoviruses in an orthotopic model of advanced lung cancer 2006 ·Cancer ·Merja Särkioja, Anna Kanerva, Jarmo Salo, Lotta Kangasniemi, Minna Eriksson, Mari Raki, Tuuli Ranki, Tanja Hakkarainen, Akseli Hemminki	29
17	A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Δ24, for the treatment of advanced breast cancer 2006 ·Gene Therapy ·Tuuli Ranki, Anna Kanerva, Ari Ristimäki, (unknown), Merja Särkioja, Lotta Kangasniemi, Mari Raki, Pirjo Laakkonen, Steve Goodison, Akseli Hemminki	42
18	Infectivity-Enhanced Adenoviruses Deliver Efficacy in Clinical Samples and Orthotopic Models of Disseminated Gastric Cancer 2006 ·Clinical Cancer Research ·Lotta Kangasniemi, Tuula Kiviluoto, Anna Kanerva, Mari Raki, Tuuli Ranki, Merja Särkioja, Hongju Wu, Frank C. Marini, Krister Höckerstedt, Helena Isoniemi, Henrik Alfthan, Ulf‐Håkan Stenman, David T. Curiel, Akseli Hemminki	36
19	Combination of gemcitabine and Ad5/3-Δ24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer 2005 ·Gene Therapy ·Mari Raki, Anna Kanerva, Ari Ristimäki, R A Desmond, (unknown), Tuuli Ranki, Merja Särkioja, Lotta Kangasniemi, Akseli Hemminki	68
20	Noninvasive dual modality in vivo monitoring of the persistence and potency of a tumor targeted conditionally replicating adenovirus 2004 ·Gene Therapy ·Anna Kanerva, Kurt R. Zinn, K-W Peng, Tuuli Ranki, Lotta Kangasniemi, Tandra R. Chaudhuri, R A Desmond, Minghui Wang, Koichi Takayama, (unknown), Henrik Alfthan, Ulf‐Håkan Stenman, David T. Curiel, Akseli Hemminki	47

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact